Diebold Nixdorf Inc (DBD)

Oct 29, 2026

Diebold-Nixdorf reported increased third-quarter numbers, with net income of $7.1 million on $994 million in revenue, but softened its full-year predictions due to increased costs. The North Canton company also announced a new $250 million stock repurchase program.

Oct 28, 2026

Shares of Diebold Nixdorf (DBD) fell 12% after the company reported third-quarter 2026 results and lowered its full-year guidance for revenue, adjusted EBITDA, and adjusted earnings per share. While third-quarter revenue and adjusted earnings beat estimates, the updated full-year outlook, particularly the reduced EBITDA and earnings guidance, caused investor concern. The company cited a shift in revenue mix and cost pressure from raw materials as reasons for the outlook change.

Oct 28, 2026

Diebold Nixdorf reported solid Q3 2026 results with a 5% increase in revenue to $991 million and adjusted EBITDA to $128 million, driven by growth in banking and double-digit retail expansion. The company announced a new $250 million share repurchase program, reflecting confidence in its long-term outlook, despite revising full-year guidance due to elevated component costs and an unfavorable product mix. Strategic collaborations, such as with Euronet for ATM outsourcing, and innovations like Smart Vision AI, are expected to fuel future growth and operational efficiencies across both banking and retail segments.

Oct 28, 2026

Diebold Nixdorf (NYSE:DBD) reported Q3 2026 revenues that surpassed Wall Street's expectations, with a 5.2% year-on-year increase to $994.3 million and non-GAAP profit per share beating estimates by 6.4%. However, the company lowered its full-year revenue and adjusted EPS guidance, leading to a slight dip in share price immediately after the report. Despite beating quarterly estimates, the softer full-year outlook suggests that newer products and services may not significantly boost revenue performance in the near term.

Oct 28, 2026

Diebold Nixdorf (DBD) reported Q3 earnings of $1.34 per share, surpassing the Zacks Consensus Estimate of $1.31, despite being lower than $1.39 a year ago. The company's revenues reached $994.3 million, exceeding the consensus estimate by 2.92% and outperforming prior-year revenues of $945.2 million. Despite these beats, DBD shares have declined 1.8% year-to-date, while the S&P 500 gained 12.8%.